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Baldassano S, Liu S, Qu M, Mulè F, Wood JD. Glucagon-like
peptide-2 modulates neurally evoked mucosal chloride secretion in
guinea pig small intestine in vitro. Am J Physiol Gastrointest Liver
Physiol 297: G800–G805, 2009. First published July 23, 2009;
doi:10.1152/ajpgi.00170.2009.—Glucagon-like peptide-2 (GLP-2) is
an important neuroendocrine peptide in intestinal physiology. It in-
fluences digestion, absorption, epithelial growth, motility, and blood
flow. We studied involvement of GLP-2 in intestinal mucosal secre-
tory behavior. Submucosal-mucosal preparations from guinea pig
ileum were mounted in Ussing chambers for measurement of short-
circuit current (Isc) as a surrogate for chloride secretion. GLP-2 action
on neuronal release of acetylcholine was determined with ELISA.
Enteric neuronal expression of the GLP-2 receptor (GLP-2R) was
studied with immunohistochemical methods. Application of GLP-2
(0.1–100 nM) to the serosal or mucosal side of the preparations
evoked no change in baseline Isc and did not alter transepithelial ionic
conductance. Transmural electrical field stimulation (EFS) evoked
characteristic biphasic increases in Isc, with an initially rapid rising
phase followed by a sustained phase. Application of GLP-2 reduced
the EFS-evoked biphasic responses in a concentration-dependent
manner. The GLP-2R antagonist GLP-2-(3-33) significantly reversed
suppression of the EFS-evoked responses by GLP-2. Tetrodotoxin,
scopolamine, and hexamethonium, but not vasoactive intestinal pep-
tide type 1 receptor (VPAC1) antagonist abolished or reduced to near
zero the EFS-evoked responses. GLP-2 suppressed EFS-evoked ace-
tylcholine release as measured by ELISA. Pretreatment with GLP-2-
(3-33) offset this action of GLP-2. In the submucosal plexus, GLP-2R
immunoreactivity (-IR) was expressed in choline acetyltransferase-IR
neurons, somatostatin-IR neurons, neuropeptide Y-IR neurons, and
vasoactive intestinal peptide-IR neurons. We conclude that submuco-
sal neurons in the guinea pig ileum express GLP-2R. Activation of
GLP-2R decreases neuronally evoked epithelial chloride secretion by
suppressing acetylcholine release from secretomotor neurons.
enteric nervous system; gastrointestinal hormones; intestine; mucosal
secretion
THE DIGESTIVE TRACT USES NEUROENDOCRINE peptides in multiple
signaling functions. They may function as neurotransmitters,
hormones, or mediators released in paracrine fashion (7). One
such peptide is glucagon-like peptide-2 (GLP-2), which is a
33-amino acid peptide secreted by intestinal endocrine L cells
in response to nutrient intake (37). It acts as a hormone that has
multifaceted signaling functions, which include 1) action as a
mucosal trophic factor that increases bowel weight and nutrient
absorption; 2) enhanced capacity for carbohydrate, amino acid,
and lipid absorption due to augmented activity of epithelial
brush-border enzymes and nutrient transporters; 3) enhanced
enterocyte proliferation and suppression of crypt cell death;
4) restoration of epithelial growth following periods of fasting;
5) maintenance of mucosal integrity by enhancement of intes-
tinal barrier function and decrease in transcellular and paracel-
lular epithelial permeability; 6) suppression of gastric acid
secretion and motility; and 7) action as an anti-inflammatory
agent, which reduces mucosal inflammatory cytokine produc-
tion, crypt cell proliferation, and apoptosis (4, 5, 10–14, 23, 28,
30, 32, 33, 37).
Results from Phase II and III trials suggest that GLP-2
action, as a growth factor, has therapeutic potential for short
bowel syndrome and gastrointestinal disorders associated with
mucosal damage (e.g., inflammatory bowel disease) (38). Im-
provement of bowel adaptation after resection may account in
part for GLP-2 efficacy to enhance intestinal absorption and
thereby reduce patient dependence on parenteral nutrition. The
action of GLP-2 is initiated by binding to a specific receptor.
Receptor activity is terminated by enzymatic action of dipep-
tidyl peptidase IV, which starts at the NH2-terminal and gen-
erates the inactive truncated fragment, GLP-2-(3-33) (12).
Therapeutic strategies include treatment with enzyme-resis-
tance analogs, one of which is GLP-2 (h[Gly 2] GLP-2),
known as teduglutide or GATTEX. Efficacy of teduglutide was
found in placebo-controlled Phase III trials (21, 25, 34). A
second strategy, which has shown promise in preclinical mod-
els of intestinal inflammatory damage, is to prolong the action
of GLP-2 at its receptor by inhibiting dipeptidyl peptidase
IV (38).
GLP-2 receptor. The GLP-2 receptor (GLP-2R) is a G
protein-coupled receptor expressed mainly in the gut and brain.
Nevertheless, the exact cellular localization, particularly in the
intestine, is unresolved. Others reported expression of GLP-2R
in human enteroendocrine cells (39) and in human and rodent
subepithelial myofibroblasts (28). Mice express messenger
RNA for GLP-2R in enteric neurons, but not the intestinal
epithelium (3). In human and porcine intestine, GLP-2R local-
izes to vasoactive intestinal peptide (VIP)-immunoreactive
neurons and to enteroendocrine cells (20).
Epithelial chloride secretion. Data for effects of GLP-2 on
mucosal chloride secretion are generally unavailable. Chloride
secretion receives attention because it is a major determinant
for movement of NaCl and H2O across the mucosal epithelium
into the intestinal lumen. Opening of chloride channels ele-
vates the intraluminal concentration of chloride followed by
movement of Na down its electrochemical gradient. As NaCl
accumulates in the lumen, water moves across the mucosa
down the osmotic gradient and this increases the liquidity of
the intestinal contents. The enteric nervous system regulates
chloride secretion (7). We aimed to test the hypothesis that
GLP-2 action on neurons in the submucosal division of the
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enteric nervous system is a factor in regulation of chloride
secretion.
MATERIALS AND METHODS
Tissue preparation. Male albino Hartley guinea pigs weighing
300–400 g were killed by stunning and exsanguination from the
cervical vessels according to procedures reviewed and approved by
the Ohio State University Laboratory Animal Care and Use Commit-
tee and the United State Department of Agriculture inspectors.
Segments of the ileum were removed and placed in ice-cold Krebs
solution containing (in mM) 120.9 NaCl, 5.9 KCl, 1.2 MgCl2, 1.2
NaH2PO4, 14.4 NaHCO3, 2.5 CaCl2, and 11.5 glucose. The segments
were opened along the mesenteric border, the intraluminal contents were
removed, and the segments were stretched tautly and pinned flat in a
Sylgard-lined Petri dish. For immunohistochemical studies, the tissues
were immersed in Zamboni’s fixative (4% formaldehyde plus 0.2% picric
acid in 0.1 M sodium phosphate buffer, pH 7.0) for 3 h at room
temperature. After fixation, the tissues were washed three times for 10
min each time in phosphate-buffered saline (PBS; 0.9% NaCl in 0.1 M
sodium phosphate buffer, pH 7.0). Whole mounts of the submucosal
plexus were obtained from these segments. To enhance immunostaining
for vasoactive intestinal peptide (VIP) in ganglion cell somas, some
preparations were incubated in Dulbecco’s modified Eagle’s medium,
containing 40 M colchicine at 37°C for 4 h prior to fixation. After
incubation, the tissues were fixed and processed as described above.
Ussing chamber methods. The muscularis externa, together with
the myenteric plexus, was removed by microdissection to obtain
flat-sheet preparations for the Ussing chamber studies. The submuco-
sal plexus remained intact with the mucosa. The flat-sheet prepara-
tions of the submucosa/mucosa were mounted between halves of
Ussing flux chambers, which had a total cross-sectional area of 0.64
cm2. The tissues were bathed on both sides, with 10 ml of oxygenated
(95% O2 and 5% CO2) Krebs solution, maintained at 37°C by
circulation from a temperature controlled water bath. Each Ussing
chamber was equipped with a pair of Ag-AgCl electrodes connected
via Krebs-agar bridges to calomel half-cells for measurement of
transmural potential difference (PD). A second pair of electrodes was
connected to an automated voltage-clamp amplifier to inject the
required short-circuit current (Isc) to maintain a zero PD between the
PD-sensing bridges. The current necessary to change the transepithe-
lial PD by 2.5 mV was used to monitor tissue conductance, calculated
according to Ohm’s law, as a determinant of tissue viability. Isc,
measured in microamperes per square centimeter, was monitored by a
voltage-clamp apparatus (DVC-1000; World Precision Instruments,
Sarasota, FL) and displayed on a chart recorder (Dash IV; Astro-Med,
West Warwick, RI). Electrical current passed between pairs of alu-
minum foil electrodes placed on the submucosal surface of the tissue
at the intersection between the two halves of the Ussing chamber
activated the submucosal neurons in the preparations (8). Grass SD 88
stimulators (Grass Instruments, Quincy, MA) supplied electrical cur-
rent to the electrodes. The stimulus parameters were stimulus strength
1–5 mA, frequency 10 Hz, pulse duration 0.5 ms, total stimulus
duration 90 s. Measurements of the change in Isc during electrical
stimulation were calculated as the difference between the peak re-
sponse and baseline Isc before stimulation.
Experimental protocol. We allowed the preparations to equilibrate
for 20 min at 37°C before application of electrical field stimulation
(EFS), after which stimulation at 5-min intervals evoked reproducible
responses, and then repeated the stimulation in the presence of
increasing cumulative concentrations of GLP-2 (0.1–100 nM). The
incubation time for each concentration was 7 min. In a different series
of experiments, GLP-2 was tested 30 min after placement of GLP-2-
(3-33) (10 nM) in the Ussing chambers. GLP-2-(3-33) is a murine
GLP-2R antagonist (31). Following discovery that GLP-2 suppressed
EFS-evoked secretory responses, we tested GLP-2 in the presence of
the muscarinic receptor antagonist scopolamine (1 M), the nicotinic
receptor antagonist hexamethonium (100 M), and a selective antag-
onist of VIP type 1 (VPAC1) receptor (1 M). These agents were
added 20 min before addition of GLP-2.
ACh release. We studied acetylcholine (ACh) release from flat-
sheet preparations of submucosa/mucosa mounted between the halves
of Ussing chambers. Each half-chamber was filled with agar to reduce
the volume to 300 l. Electrode and fluid ports were blocked with
agar. The preparations were incubated with GLP-2 alone, GLP-2 and
GLP-2-(3-33) applied in combination, or GLP-2-(3-33) alone for 30
min followed by EFS, as described above. The contents of the
chambers were collected immediately at the end of stimulation and
stored at 20°C for subsequent analysis of ACh release.
Immunofluorescence. Table 1 lists sources for all primary and
secondary antibodies and the optimal dilutions used in the immuno-
histochemical study. Whole-mount preparations of submucosal plexus
were placed in PBS containing 10% normal donkey serum and 0.3%
Triton X-100 for 30 min at room temperature to minimize nonspecific
binding and increase tissue permeability. The tissues were incubated
overnight at 4°C in primary antibodies for GLP-2R or a mixture of
primary antibodies (Table 1) for double labeling. Competition with
the control peptide (cat. no. LS-P1312, Lifespan Biosciences) estab-
lished antibody specificity for GLP-2R. The GLP-2R antibody was
preabsorbed with the control peptide for 2 h and then used for
immunohistochemical localization of the receptor. After being washed
with PBS, the tissues were incubated with a single secondary antibody
or a mixture of appropriate secondary antibodies conjugated with
fluorescein isothiocyanate (FITC) or indocarbocyanin (Cy3), at room
temperature, for 1 h followed by washing in PBS and mounting with
VECTASHIELD (Vector, Burlingame, CA). Fluorescence labeling
was examined with a Nikon Eclipse 90i fluorescence microscope
(Nikon Instruments, Melville, NY). Photomicrographs were acquired
with a Cool Snap HQ2 monochrome digital camera and MetaMorph
software (Molecular Devices, Sunnyvale, CA), stored on disk, and
analyzed with MetaMorph. Images were minimally adjusted for
brightness and contrast by using MetaMorph. Immunoreactivity (IR)
for the GLP-2R and enteric neurochemical codes and numbers of
double-labeled cells were assessed in randomly chosen ganglia situ-
ated throughout the preparations.
Chemicals. The following drugs were used and stock solutions
were prepared in distilled H2O or dimethyl sulfoxide. Scopolamine
and hexamethonium bromide were purchased from Sigma (St. Louis,
MO), tetrodotoxin from Alomone Labs (Jerusalem, Israel), GLP-2
from Tocris (Elisville, MO), GLP-2-(3-33) from California Peptide
Research (Napa, CA), and VPAC1 receptor antagonist [Ac-His1,
D-Phe2, Lys15, Arg16, Leu27]-VIP(3-7)-GRF(8–27) from Phoenix
Table 1. Codes and sources of primary and secondary
antibodies
Antigen Host Code Dilution Source
Anti-Hu Mouse A212-71 1:50 Molecular Probes
GLP-2R Rabbit LS-A1312 1:200 Lifespan Biosciences
GLP-2 peptide Rabbit LS-P1312 1:100 Lifespan Biosciences
ChAT Goat AB144P 1:100 Chemicon
NPY Sheep AB1583 1:1500 Chemicon
Somatostatin Rat MAB354 1:200 Chemicon
VIP Sheep AB1581 1:1000 Chemicon
Calretinin Goat AB1550 1:2500 Chemicon
Rabbit IgG Donkey Cy3 711-165-152 1:500 Jackson
Mouse IgG Donkey FITC 715-095-150 1:100 Jackson
Goat IgG Donkey FITC 713-095-003 1:100 Jackson
Sheep IgG Donkey FITC 713-095-147 1:100 Jackson
Rat IgG Donkey FITC AP189F 1:100 Chemicon
Anti-Hu: anti-human neuronal protein; GLP-2R, glucagon-like peptide (GLP-2)
receptor; ChAT, choline acetyltransferase; NPY, neuropeptide Y; VIP, vasoactive
intestinal peptide.
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Pharmaceuticals. GLP-2 and GLP-2-(3-33) were dissolved in di-
methyl sulfoxide (DMSO, 0.1% final concentration). Application of
DMSO alone did not alter basal Isc or responses to EFS as reported
earlier (15).
Data analysis and statistics. Preparations from the same animal
were studied simultaneously in four Ussing chamber setups. Data are
expressed as means  SE; n values refer to the number of animals.
Statistical significance was determined with paired Student’s t-test
between control and experimental populations or ANOVA followed
by Bonferroni post hoc test, when appropriate. Differences were
considered significant at P  0.05.
Labeled neurons in 30 submucosal ganglia were counted in the
immunohistochemical studies. Total number of neurons labeled with
a specific neuronal marker and the percent overlap of those markers
with GLP-2R were determined.
RESULTS
Baseline Isc was 145.4  2.5 A/cm2 (n  15) and the
corresponding conductance was 36.8  1 mS/cm2. Application
of GLP-2 (0.1–100 nM) to the serosal or mucosal side of the
preparations evoked no change in the baseline Isc (143.8  1.9
A/cm2, n  8, P  0.05) and did not alter the total tissue
conductance (35.6  1.2 mS/cm2, n  8, P  0.05).
EFS evoked a biphasic increase in Isc, which consisted of a
spikelike rapid rise followed by a second sustained response
(Fig. 1). Tetrodotoxin (100 nM, n  3) abolished both phases
of the EFS-evoked responses (Fig. 1). Blockade of the EFS-
evoked responses by tetrodotoxin was evidence that the re-
sponses were neurally mediated.
GLP-2 (0.1–100 nM), added to the serosal side of the
chamber, produced a concentration-dependent reduction in the
first and second phases of the EFS-evoked response (Figs. 1
and 2). This action of GLP-2 (0.1–100 nM) was suppressed by
the GLP-2R antagonist GLP-2-(3-33) (Fig. 2).
Application of the muscarinic receptor antagonist scopol-
amine (1 M) alone abolished the first phase and significantly
reduced the second phase of the EFS-evoked responses. In the
presence of scopolamine, GLP-2 in a concentration range of
0.1–100 nM failed to suppress further the first and second
phases of the EFS-evoked secretory responses (Fig. 3A).
Exposure to 100 M hexamethonium, which is a nicotinic
receptor antagonist, reduced both the first and the second phase
of the EFS-evoked responses. In the presence of hexametho-
nium, GLP-2 (0.1–100 nM) failed to suppress further the
first and second phases of the EFS-evoked secretory re-
sponses (Fig. 3B).
The presence of the VIP receptor antagonist VPAC1 (1 M)
in the bathing medium on the serosal side of the preparation did
not modify the first phase but reduced significantly the second
phase of the EFS-evoked responses. In the presence of
VIPAC1, GLP-2 (0.1–100 nM) continued to suppress both
the first and second phases of the EFS-evoked secretory
responses (Fig. 3C).
ACh release. The results with tetrodotoxin and cholinergic
receptor antagonists suggested that GLP-2 acted to suppress
neuronal release of ACh from secretomotor neurons. We tested
this by measuring the amount of ACh released from the
submucosal-mucosal preparations by EFS in the absence or
presence of GLP-2. The presence of GLP-2 (10 nM) signifi-
cantly reduced the released ACh (Fig. 4). Pretreatment with 10
nM GLP-2-(3-33) reduced suppression of ACh release by
GLP-2 to near zero (Fig. 4).
Immunofluorescence. We used immunohistochemical stain-
ing to localize GLP-2R in whole-mount preparations of the
submucosal plexus and found that ganglion cell bodies ex-
pressed IR for GLP-2R at the cell surface (Fig. 5A). Preab-
sorption of the anti-GLP-2R antibody with the immunogen
(i.e., synthetic peptide-keyhole limpet hemocyanin conjugated)
quenched all immunofluorescence (Fig. 6C).
IR for HuC/D is a convenient panneuronal marker for all
enteric neurons (24). Double labeling with anti-Hu showed that
GLP-2R-IR nerve cell bodies accounted for about one-half of
the total population of anti-Hu-IR neurons in the submucosal
plexus (Fig. 5, A–C; Table 2). Double-label immunohisto-
chemistry for enteric neurochemical codes identified the major
classes of ganglion cells that expressed GLP-2R-IR. GLP-
2R-IR was expressed by neurons that expressed IR for choline
acetyltransferase, which is a neurochemical code for cholin-
ergic secretomotor/vasodilator motoneurons (Fig. 5, D–F; Ta-
ble 2) (17, 18). About three-fourths of the neurons with IR for
neuropeptide Y coexpressed GLP-2R-IR (Fig. 5, G–I; Table 2).
Neuropeptide Y is a code for cholinergic secretomotor/nonva-
sodilator motoneurons in the guinea pig submucosal plexus
(17, 18). More than half of the neurons with IR for somatosta-
tin coexpressed GLP-2R-IR (Fig. 5, G–I; Table 2). Soma-
tostatinergic neurons in the guinea pig submucosal plexus
provide inhibitory synaptic input to secretomotor neurons in
the guinea pig submucosal plexus (30). Fewer than half of the
neurons with IR for VIP expressed GLP-2R-IR (Fig. 5, O–Q;
Table 2). Guinea pig submucosal neurons, which express
VIP-IR, belong to the noncholinergic secretomotor/vasodilator
class of submucosal neurons (17, 18). A much smaller propor-
tion (1%) of the submucosal neurons that expressed calreti-
nin-IR also expressed GLP-2-IR (Table 2).
DISCUSSION
We studied GLP-2 because it is an important factor in the
regulation of the morphology, function, and integrity of the
intestinal mucosa and it is emerging as a novel therapeutic
modality in a variety of conditions associated with intestinal
injury (33, 34, 38). We aimed to investigate, in vitro, a putative
Fig. 1. Electrical field stimulation (EFS) evoked increases in short-circuit
current (Isc), which consisted of a spikelike first phase and a delayed second
phase. The first and second phases represent cholinergically evoked and
putative peptidergic/cholinergic-evoked chloride secretion, respectively. glu-
cagon-like peptide-2 (GLP-2), applied in the serosal compartment of the
Ussing chamber, suppressed the first and second phases in a concentration-
dependent manner. Tetrodotoxin (TTX) abolished both the first phase and the
delayed second phase.
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role for GLP-2 in enteric nervous regulation of intestinal
secretion.
Ussing chamber methods revealed no changes in baseline Isc
or the corresponding conductance during application of GLP-2,
which suggests that it does not change ionic channel conduc-
tance or mucosal barrier function when applied in vitro. This
disagrees with earlier reports of others that GLP-2 reduced
passive permeability to ions and restricted transmucosal move-
ment of macromolecules, in vivo, in chronic animal models for
food allergy, stress, or diabetes (2, 5, 6, 20). Our study in vitro
differs from the in vivo studies reported by others and might
account for the discrepancy. Chronic administration of GLP-2
in vivo reportedly tightens the mucosal barrier to movement of ions
and macromolecules, whereas acute application of GLP-2 in our
Ussing chamber studies in vitro did not change Isc or ionic
conductance.
Our finding that functional classes of neurons in the submu-
cosal plexus expressed GLP-2R and that application of GLP-2
suppressed EFS-evoked increases in Isc suggest that GLP-2
suppression of chloride secretion reflects action at enteric
ganglion cells in the submucosal plexus. The inhibitory action
of GLP-2 on EFS-evoked Isc appears to be specific because it
was concentration-dependent and suppressed by GLP-2-(3-33),
which is an antagonist at GLP-2R (29). GLP-2-(3-33) alone did
not affect the EFS-evoked biphasic responses, which suggests
that it behaved like an antagonist at receptors on neurons in our
preparations and that it had no direct action on the enterocytes
or on paracellular epithelial conduction pathways.
The first and second phases of EFS-evoked Isc responses
reflect muscarinic cholinergic and VIPergic-cholinergic trans-
mission at neuroepithelial junctions, respectively (9, 23). Our
pharmacological data suggest that the inhibitory action of
GLP-2 is mainly in pathways with cholinergic neurotransmis-
sion and minimal in VIPergic pathways. The finding that the
muscarinic receptor antagonist scopolamine suppressed the
inhibitory action of GLP-2 on neurally evoked Isc responses
was consistent with an action of GLP-2 on cholinergic secre-
tomotor pathways. Scopolamine suppression of the inhibitory
action of GLP-2 was probably due to blockade of muscarinic
transmission at the neuroenterocyte junctions, which would
prevent EFS-evoked responses and in this manner mask the
inhibitory action of GLP-2 on the responses.
EFS directly activates secretomotor neurons to release their
neurotransmitters at the neuroepithelial junctions and simulta-
neously activates interneurons in the enteric microcircuitry to
release their neurotransmitters at synapses with other interneu-
Fig. 3. Pharmacology for action of GLP-2 on first and second phases of neurally mediated Isc responses to transmural EFS. A: GLP-2 (10 nM) applied in the
presence of the muscarinic receptor antagonist scopolamine (1 M). B: GLP-2 (10 nM) applied in the presence of the nicotinic receptor antagonist
hexamethonium (100 M). C: GLP-2 (10 nM) applied in the presence of the vasoactive intestinal peptide (VIP) receptor antagonist VPAC1 (1 M). Isc is the
difference between baseline current and evoked current. Data points are means  SE. Each mean represents data for ileal preparations from 5 guinea pigs. *P 
0.05 for GLP-2 relative to control; #P  0.05 for GLP-2 relative to VPAC1.
Fig. 2. Cumulative concentration-response curves for
the inhibitory action of GLP-2 on the first and second
phases of Isc evoked by EFS. A: inhibition of the first
phase of EFS-evoked Isc by GLP-2 alone (■) or in the
presence of the antagonist GLP-2-(3-33) (E). B: inhi-
bition of the second phase of EFS-evoked Isc by GLP-2
alone (■) or in the presence of the antagonist GLP-2-
(3-33) (E). Data are expressed as percent inhibition of
EFS-evoked Isc by GLP-2. Data points are means 
SE. Each mean is data for preparations from 6 animals.
*P  0.05 for GLP-2-(3-33) relative to GLP-2 alone.
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rons. Enteric interneurons, which are connected into networks
by nicotinic synapses, provide excitatory nicotinic synaptic
input to the secretomotor neurons (35). Suppression of the
inhibitory action of GLP-2 by the nicotinic receptor antagonist
hexamethonium is evidence for an action of GLP-2 to suppress
neuronal release of ACh at synapses in the interneuronal
microcircuitry and for action to suppress ACh release at exci-
tatory nicotinic synapses on secretomotor neurons. Failure of
the VIP receptor antagonist VPAC1 to alter the inhibitory
action of GLP-2 suggests that GLP-2’s enteric neuronal action
is restricted to cholinergic signal pathways to the mucosa. Our
finding that GLP-2 reduced the neuronal release of ACh into
the bathing medium and that the GLP-2R antagonist offset this
action of GLP-2 supports this conclusion.
Absence of suppression of EFS-evoked Isc responses by a VIP
receptor antagonist is puzzling in view of our finding of expres-
sion of GLP-2R-IR by the class of ganglion cells with VIP as their
chemical code. This might reflect differences in parallel secreto-
motor pathways for chloride and bicarbonate secretion. VIP is a
neurotransmitter at neuroepithelial junctions in a neural pathway
that activates chloride secretion and a separate pathway that
stimulates bicarbonate secretion (16). Expression of the GLP-2R
by VIPergic secretomotor neurons in the bicarbonate stimulatory
pathway and not by VIPergic secretomotor neurons in the chloride
pathway might explain the discrepancy. GLP-2 relaxes the mouse
stomach by stimulating release of VIP from inhibitory motoneu-
rons in the gastric enteric nervous system (1). An excitatory action
of GLP-2 on VIPergic secretomotor neurons in a bicarbonate
secretory pathway might be the case. Nevertheless, this has not
been confirmed.
Our evidence for GLP-2 inhibitory influence on intestinal
chloride secretion is reminiscent of reports for gastric secretion in
which GLP-2 suppresses the stimulation of acid secretion evoked
by pentagastrin or sham feeding in humans (26, 27). These effects
of GLP-2 on acid secretion in the stomach, like the effects on
neurally evoked chloride secretion in the intestine in vitro, might
reflect suppression of ACh release at neuroeffector junctions.
Whether the actions of GLP-2 in vitro are indicative of physio-
logically significant action in vivo is undetermined because phys-
iological concentrations of GLP-2 in the plasma of the guinea pig
model are unknown.
Fig. 4. Release of acetylcholine evoked by transmural EFS. GLP-2 (10 nM),
when applied alone in the serosal compartment of the Ussing chamber,
suppressed neural release of acetylcholine evoked by transmural EFS. Coap-
plication of the GLP-2 receptor antagonist GLP-2-(3-33) (10 nM) with GLP-2
(10 nM) reversed suppression by GLP-2 of acetylcholine release during
transmural EFS. Data points are means  SE.
Fig. 5. Expression of GLP-2R immunoreactivity (IR) in whole mounts of
guinea pig small intestinal submucosal plexus. A1–3: coexpression of GLP-
2R-IR with anti-Hu-IR, which marks all enteric neurons, reveals expression
GLP-2R-IR restricted to neuronal cell bodies. B1–3: coexpression of GLP-
2R-IR with choline acetyltransferase (ChAT-IR), which is a neurochemical
marker for secretomotor neurons. C1–3: coexpression of GLP-2R-IR with
neuropeptide Y (NPY-IR), which is a neurochemical marker for secretomotor/
nonvasodilator motoneurons when coexpressed with ChAT-IR. Scale bars 
20 m.
Fig. 6. Expression of GLP-2R IR in whole mounts of guinea pig small
intestinal submucosal plexus. A1–3: coexpression of GLP-2R-IR with soma-
tostatin-IR, which is a neurochemical marker for interneurons that provide
inhibitory input to secretomotor neurons. B1–3: coexpression of GLP-2R-IR
with vasoactive intestinal peptide (VIP-IR), which is a neurochemical marker
for noncholinergic secretomotor/vasodilator motoneurons. C1: GLP-2R-IR.
C2: GLP-2R-IR after preabsorbing the antibodies with the corresponding
blocking peptide provided by the manufacturer.
Table 2. GLP-2R-IR in relation to chemical codes







Data are means  SE from 4 preparations. IR, immunoreactivity.
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Conclusion. Our results are new evidence that functional
subclasses of neurons in the submucosal plexus of guinea pig
small intestine express the GLP-2R. GLP-2 acts at the receptor
to suppress ACh release from secretomotor neurons at musca-
rinic junctions with the epithelium and from interneurons in the
enteric neural networks, which have nicotinic synaptic connec-
tions that control mucosal chloride secretion. This action of
GLP-2 translates to suppression of secretion of NaCl and H2O
and a decrease in the liquidity in the intestinal lumen at the
organ system level of organization.
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